MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Grows Stock Holdings in DexCom, Inc. $DXCM

Key Points

• MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its ownership in DexCom, Inc. by purchasing an additional 63,320 shares, raising its total stake by 14.3% to 506,321 shares valued at $34.57 million.
• Several hedge funds including Horizon Investments LLC and Nia Impact Advisors LLC have also increased their positions in DexCom, contributing to the total institutional ownership of the company's stock at 97.75%.
• Analysts have a generally positive outlook on DexCom, with multiple firms raising their target prices and ratings, resulting in a consensus rating of "Moderate Buy" with a target price of $99.89.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 14.3% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 506,321 shares of the medical device company's stock after acquiring an additional 63,320 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned 0.13% of DexCom worth $34,577,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Golden State Wealth Management LLC lifted its holdings in shares of DexCom by 211.2% in the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after acquiring an additional 264 shares during the last quarter. Zions Bancorporation National Association UT bought a new stake in shares of DexCom in the 1st quarter worth approximately $27,000. Heck Capital Advisors LLC bought a new stake in shares of DexCom in the 4th quarter worth approximately $38,000. Alpine Bank Wealth Management bought a new stake in shares of DexCom in the 1st quarter worth approximately $40,000. Finally, Private Trust Co. NA lifted its holdings in shares of DexCom by 99.4% in the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock worth $46,000 after acquiring an additional 335 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

DexCom Trading Up 0.4%

Shares of NASDAQ:DXCM traded up $0.31 on Friday, hitting $76.31. The company had a trading volume of 795,741 shares, compared to its average volume of 3,922,925. The firm's 50-day simple moving average is $81.01 and its two-hundred day simple moving average is $78.80. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $93.25. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $29.93 billion, a price-to-earnings ratio of 52.98, a P/E/G ratio of 1.59 and a beta of 1.48.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.45 by $0.03. The firm had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company's quarterly revenue was up 15.2% compared to the same quarter last year. During the same period last year, the company posted $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. Equities analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 1,466 shares of the firm's stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $80.00, for a total transaction of $117,280.00. Following the sale, the executive vice president owned 105,223 shares of the company's stock, valued at $8,417,840. This trade represents a 1.37% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Michael Jon Brown sold 500 shares of the firm's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $80.29, for a total transaction of $40,145.00. Following the sale, the executive vice president directly owned 94,102 shares in the company, valued at approximately $7,555,449.58. The trade was a 0.53% decrease in their position. The disclosure for this sale can be found here. Insiders sold 15,237 shares of company stock worth $1,263,480 in the last 90 days. Insiders own 0.32% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Argus assumed coverage on shares of DexCom in a research report on Thursday, August 21st. They set a "buy" rating and a $100.00 price target for the company. Truist Financial assumed coverage on shares of DexCom in a research report on Monday, June 16th. They set a "buy" rating and a $102.00 price target for the company. Citigroup reissued a "buy" rating and set a $102.00 price target (up previously from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Wall Street Zen cut shares of DexCom from a "strong-buy" rating to a "buy" rating in a research report on Sunday, August 10th. Finally, Mizuho increased their price target on shares of DexCom from $95.00 to $100.00 and gave the company an "outperform" rating in a research report on Wednesday, July 16th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $99.89.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.